Mitochondrial bioenergetics-SASP crosstalk determines senolytic efficacy in therapy-induced senescence.

Àngela Llop-Hernández, Sara Verdura, Júlia López, Begoña Martin-Castillo, Javier A Menendez, Elisabet Cuyàs

Program Against Cancer Therapeutic Resistance (ProCURE), Catalan Institute of Oncology, Girona, Spain.Program Against Cancer Therapeutic Resistance (ProCURE), Catalan Institute of Oncology, Girona, Spain. · pubmed

Paper

Abstract

Mitochondria integrate senescence and apoptotic fates, yet it is unclear whether their ability to oxidize different fuels for energy production influences their vulnerability to senolytics in therapy-induced senescence (TIS). Using MitoPlates™ technology, we functionally mapped the mitophenotypes of TIS cancer cells by quantifying electron transport chain (ETC) flux from various NADH/FADH

The following analysis is generated by AI and may contain errors. It is separate from the authors’ abstract and is not peer review.

Research summary

The paper claims that mitochondrial bioenergetics and senescence-associated secretory phenotype (SASP) interactions influence the effectiveness of senolytic therapies in therapy-induced senescence. This research is relevant as it explores mechanisms that could potentially target the root causes of aging and senescence, which are critical for developing therapies aimed at lifespan extension and age-related diseases.

Author of this paper? Send a correction.